If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
372
results.
Updated on
24/10/2026 [08:50:00]
Results 200 to 225 of 372
Absstract of: US20260279589A1
The present invention relates to protein markers relevant to mild cognitive impairment (MCI) and Alzheimer's disease (AD), especially those detectable in blood samples. Thus, methods and compositions are provided for risk assessment and early diagnosis of MCI and AD based on the analysis of these protein markers. Further provided are methods and compositions useful for evaluating the efficacy of a therapy for MCI or AD.
Absstract of: US20260276625A1
Provided is a screening method for searching for a new autophagy-inducing compound. In the present invention, a new autophagy-inducing compound is searched for using at least one of the following characteristics: (1) having high binding affinity for DEAD-box RNA helicase; (2) approximating DEAD-box RNA helicase and p62 to promote interaction; and (3) promoting droplet formation of DEAD-box RNA helicase and p62.
Absstract of: US20260274931A1
Disclosed herein are methods of conducting clinical trials in Alzheimer's disease (AD). Methods of selecting a medicament and treating an AD subject are disclosed. Methods, systems, kits, and devices for selecting a subject in AD clinical trials and treatment protocols are disclosed herein.
Absstract of: US20260276627A1
0000 Provided is a method for inhibiting macrophage neurotoxicity, the method comprising increasing expression of Aurora kinase in macrophages, wherein the Aurora kinase includes AURKA, AURKB, or a combination thereof. The expression may be increased by co-culturing the macrophages with neurons such as dorsal root ganglion sensory neurons, hippocampal neurons, dopaminergic neurons, motor neurons, cerebellar granule cells, thalamic neurons, or spinal cord neurons.
Absstract of: US20260276648A1
Methods for identifying tumor tissue and determining a margin of a tumor to be resected in a subject are disclosed within. The methods utilize guanidinoacetic acid (GAA) as a tissue biomarker of malignant brain tumors. The presently disclosed subject matter further relates to methods for providing a diagnosis or prognosis about a cancer in a subject.
Absstract of: US20260276655A1
The present disclosure relates to biomarkers and uses thereof in methods for selecting a patient diagnosed with amyotrophic lateral sclerosis (ALS) for an ALS therapy. The present disclosure further relates to methods for identifying the severity of ALS in a patient, treating an ALS patient, and monitoring efficacy of an ALS treatment.
Absstract of: US20260276647A1
The present invention makes it possible to acquire biological information relating to an examination subject more easily or more accurately and to provide the biological information to a user. This living organism examination method for providing biological information relating to an examination subject (1), which is a living organism, by analyzing biological components in the sweat of the examination subject includes: a collection step (S101) for collecting sweat from an examination site of the examination subject (1); a measurement step (S102) for measuring a biological component profile of the sweat collected in the collection step; a biological information acquisition step (S103) for acquiring biological information relating to the examination subject (1) on the basis of the biological component profile measured in the measurement step; and an information provision step (S104) for providing the biological information relating to the examination subject, acquired in the biological information acquisition step, in a predetermined format.
Absstract of: US20260276634A1
The present invention relates to an in vitro method for evaluating the state of intestinal permeability of a subject and, consequently, for the diagnosis of diseases or dysfunctions associated with intestinal hyper-permeability. More specifically, the procedure allows measuring using a common food component the amount of dietary antigen that can traverse a dysfunctional intestine. The procedure allows for the development of analytical products and processes within the framework of the medical devices industry.
Absstract of: US20260275418A1
A method is disclosed for detecting schizophrenia, at any stage, which comprises the steps of determining the gene expression of ZNF560 in a biological sample from a subject and comparing it with the ones of a healthy individual as a control sample, wherein the subject of the biological sample is diagnosed as having schizophrenia the gene ZNF560 is overexpressed in the biological sample in comparison to the control. Also disclosed is a kit of parts to diagnose schizophrenia from a biological sample and the use of the kit of parts as a detection agent useful to diagnose schizophrenia, wherein schizophrenia could be at prodromal, acute, residual, or chronic stage.
Absstract of: WO2026192282A1
An object of the present invention is to provide a method for recommending a treatment candidate group suitable for treatment with anti-amyloid antibody therapeutics by obtaining quantitative protein analysis data from blood and selecting a patient group at high risk of conversion to dementia.
Absstract of: US20260272907A1
This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular Bruton tyrosine kinase (“BTK”) inhibitors for treatment of subjects with relapsing multiple sclerosis.
Absstract of: WO2026192093A1
The present invention provides a digital olfactory data service platform comprising: a digital olfactory data collection system including a multi-channel olfactory sensor array provided to be able to collect digital olfactory data by using various types of odor collection samples collected in a plurality of fields, and a sensing management module provided to be able to manage the odor collection samples and the digital olfactory data; a digital olfactory AI data service system including a digital olfactory data lake, a digital olfactory data service management module, and a digital olfactory data management module, storing olfactory sample-related metadata, digital olfactory data, digital olfactory recognition data, and sensor management data, providing various data management functions stored in the digital olfactory data lake, and providing functions such as product management and subscription management for data services; and an olfactory recognition AI deep learning system including an olfactory recognition deep learning model for performing AI deep learning on the digital olfactory sensor data.
Absstract of: EP4807366A2
0001 The present disclosure relates to methods, systems, and devices for performing analyses of biological nanoparticles. More specifically, the present disclosure relates to methods, systems, and devices for performing single biological nanoparticle size determination on a sample while the biological nanoparticle is in transit through a microfluidic chip. In other aspects, the present disclosure relates to methods, systems, and devices for selectively capturing biological nanoparticles on a coated planar surface, the capturing being facilitated by centrifugation.
Absstract of: WO2025099457A2
The invention relates to methods of analysing one or more protein complexes in body fluid samples using ultra-sensitive techniques such as single molecule pulldown. The methods find particular use in detecting protein complex biomarkers for the detection or diagnosis of neurodegenerative disorders. The invention also relates to novel combination biomarkers.
Absstract of: WO2025041169A1
The present invention provides a kit, a device and an in-vitro assay based on a nanozyme-based lateral flow assay utilizing para-phenylenediamine of optimal concentration 0.1mM to 10mM as a chromogenic substrate for catalytically active aptamer-conjugated gold-nanozyme, which enhances sensitivity. The chromogenic substrate produces a robust brown color upon oxidation by catalytically active nanomaterial. The brown color remains stable for weeks and presents high contrast against the background. This overcomes the limitations of ordinary LFA in detecting analytes present at critical levels that are below microgram per milliliter, often resulting in false negative results. This provides a versatile and high-sensitive point-of-care diagnostic technique for rapid screening of infectious disease antigens and the detection of biomarkers for diseases such as cancer, cardiac and neurodegenerative diseases.
Absstract of: WO2025049921A1
The present disclosure provides a near full-length long read AIRR-seq (FLAIRR-Seq) method that utilizes targeted amplification by 5' rapid amplification of cDNA ends (RACE), combined with single molecule, real-time sequencing to generate highly accurate immunoglobulin (Ig) heavy chain and light chain transcripts.
Absstract of: WO2021262706A1
Provided herein are assays that provide digital measurement methods to detect proteins and other biomolecules, e.g., at low- to mid-attomolar concentrations.
Absstract of: MX2025010847A
The antibody NEO-201 is shown to bind to Treg cells, and its use in targeting Treg cells is described. NEO-201 may be used for isolation, detection, or purification of active Treg cells and also to kill Treg cells. Therapeutic methods and combination therapies using NEO-201 optionally in combination with another agent are described.
Absstract of: CN122754497A
0001 本发明涉及生物医学技术领域，具体而言，本发明涉及一种检测老年痴呆的试剂盒及其应用。该试剂盒包含针对β‑淀粉样蛋白Aβ42和Aβ40的特异性单克隆抗体，其中抗人Aβ42单克隆抗体通过免疫Balb/c小鼠、细胞融合和杂交瘤筛选制备，其轻重链可变区序列如SEQ No.1‑6所示；抗人Aβ40单克隆抗体采用类似方法制备。试剂盒还包括预包被酶标板、标准品和酶标记检测抗体。通过ELISA方法检测患者外周血血清中Aβ42和Aβ40的水平，并计算Aβ42/Aβ40比值，用于阿尔兹海默症的诊断。该试剂盒具有灵敏特异、快速便捷、易于操作等特点，能有效区分阿尔兹海默症患者和抑郁症患者，适用于体外预筛查和诊断。
Absstract of: WO2025046049A1
The present invention relates to molecules that are capable of binding to amyloid fibril aggregates. The invention further describes methods for detecting the presence of amyloid fibril aggregates in a sample or a subject. The invention even further describes methods for treating pathologies caused by amyloid fibril aggregates.
Absstract of: CN122749439A
本申请公开了一种有机化合物及其制备方法、作为探针的应用，属于探针领域。有机化合物具有式I所示的结构其中，arene代表芳香杂环，选自萘环、喹喔啉、苯并噻二唑中的一种；R1选自羟基、甲氧基、哌啶、吗啉、久洛尼定、氰基、硝基中的一种；R2选自氯原子、溴原子、碘原子中的一种。该探针在具有淀粉样变蛋白靶向能力的同时，在体外淀粉样模型蛋白中也表现出选择性标记的特点，可以用于阿尔茨海默病模型小鼠淀粉样沉积物的组分分析，弥补了领域内缺乏对阿尔茨海默病致病蛋白的组分分析这一空白。
Absstract of: CN122749696A
0001 本发明涉及一种与强啡肽A特异性结合的人工从头设计蛋白，所述蛋白质的氨基酸序列如SEQ ID NO:1所示。本发明针对强啡肽A具有高度柔性和动态构象的特点，通过人工从头设计方法构建具有特异性识别界面的结合蛋白，可对强啡肽A的特定序列区域或优势构象进行有效识别与结合，突破了传统“锁钥模型”难以适用于无序蛋白识别的限制。
Absstract of: CN122750834A
本发明提供一种血管内皮细胞中SIRT7的应用、筛选药物方法及药物组合物、试剂盒、模型构建方法。血管内皮细胞中的SIRT7作为药物靶点在制备预防、延缓或治疗脑衰老和/或血管性痴呆的药物中的应用。血管内皮细胞中的SIRT7作为生物标志物在制备用于评估脑衰老程度或血管性痴呆风险的诊断试剂或试剂盒中的应用。
Absstract of: KR20260135747A
본 발명은 HCN1 채널의 CNBD 도메인에 특이적으로 결합하는 세계 최초의 소분자 개방제(ind_5F_3pyr, 5-플루오로-1H-인다졸-3-일-피리딘-3-일)에 관한 것이다. 알츠하이머병에서 HCN1 채널 발현이 감소하여 신경 흥분성 이상이 발생하며, 기존 HCN 약물은 모두 차단제로서 이를 해결할 수 없다. 본 발명의 화합물은 HCN1 CNBD에 cAMP보다 강하게 결합하고(ΔG = -8.08 vs -7.51 kcal/mol), 열린 상태를 안정화하며(apo ΔG = -8.32), 혈액뇌장벽을 투과하고(MW 213, TPSA 57), TRIP8b 대체를 통한 뇌 선택성을 달성한다. 119개 후보 중 가상 스크리닝과 분자동역학으로 동정되었다. JPEGpat00001.jpg5157
Nº publicación: CN122726299A 11/09/2026
Applicant:
陕西师范大学
Absstract of: CN122726299A
0001 本发明公开了一种抗人Aβ1‑40和Aβ1‑42的单克隆抗体和基于其的产品以及应用，属于单克隆抗体技术领域。所述抗体包括轻链和重链，轻链属于kappa型，重链属于IgG2b型；其轻链可变区的3个互补决定区的氨基酸序列分别如SEQ ID No.1、2、3所示；重链可变区的3个互补决定区的氨基酸序列分别如SEQ ID No.9、10、11所示。该抗体经由化学合成的人Aβ1‑20短肽偶联KLH作为抗原免疫小鼠后，经融合和数次克隆化筛选获得，能同时高效特异性识别人Aβ1‑40和Aβ1‑42，不结合BSA、KLH‑p‑Tau217、NFL等无关蛋白，平衡解离常数达皮摩尔级（Kd ≈ 51 pM），可用于人Aβ1‑40和Aβ1‑42的定量检测与体外诊断试剂盒开发，同时在Aβ相关疾病的抗体治疗中具有应用潜力。
BOPI
Electronic site
